Leerink keeps USD 20.00 target for Sarepta Therapeutics stock

Published on 10/29/2026 at 13:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Leerink kept its Hold rating for Sarepta on October 16, 2026. Sarepta Therapeutics stock trades at EUR 17.09 on October 29, 2026.

Key operating facts

Leerink Partners reiterated its Hold rating on October 16, 2026.
Sarepta reported USD 401.25 million in second-quarter 2026 revenue.
Sarepta scheduled its third-quarter results for November 5, 2026.
The company had a USD 2.0 billion market capitalization as of October 28, 2026.

SRPT, US8036071004, Illustration mit AI erstellt.

Sarepta Therapeutics (ISIN US8036071004) received a reiterated Hold rating and a USD 20.00 price target from Leerink Partners in a report dated October 16, 2026, according to The Globe and Mail. The rating keeps the analyst view unchanged while Sarepta approaches its next scheduled financial update.

Analyst view stays cautious

Leerink's target was published alongside a Hold assessment, giving investors a defined reference point for the biotechnology company's valuation. The same report cited second-quarter 2026 revenue of USD 401.25 million and a GAAP net loss of USD 4.89 million.

The revenue figure was down from USD 611.09 million in the year-earlier quarter, while the prior-year period had produced net income of USD 196.89 million, according to the linked report. Those figures make operating performance the key counterweight to the analyst target.

What does the target mean for risk?

Sarepta's second-quarter 2026 revenue decline of 34.30 percent contrasts with the company's expanding genetic-medicine pipeline. Its business focuses on RNA-based therapies and gene therapy for rare diseases, including Duchenne muscular dystrophy.

For the next catalyst, Sarepta Therapeutics said on October 22, 2026 that it will report third-quarter 2026 results after the Nasdaq Global Market closes on November 5, 2026. The company also scheduled a conference call at 4:30 p.m. ET that day.

Valuation ahead of November 5

MarketBeat reported that analysts expected third-quarter 2026 revenue of USD 352.20 million and earnings of USD 0.0740 per share. The estimate provides a concrete benchmark for the November report, particularly after the second-quarter revenue decline.

Sarepta was valued at USD 2.0 billion on October 28, 2026, with a 52-week range of USD 14.68 to USD 24.68. The company is listed on Nasdaq under the SRPT symbol, as identified in its investor-relations release.

Trading indication

Sarepta Therapeutics was trading at EUR 17.09 at Lang & Schwarz on October 29, 2026 at 1:33 p.m. CEST. The quote provides the current German-market indication ahead of the company's November reporting event.

The further course of trading is shown by the continuously updated real-time quote of Sarepta Therapeutics stock.